MedicalSentry

Health Research Company

Naprosyn

generic name is naproxen

Why is this drug subscribed ?

Prescription naproxen is used to relieve pain, tenderness, swelling, and stiffness caused by osteoarthritis (arthritis caused by a breakdown of the lining of the joints), rheumatoid arthritis (arthritis caused by swelling of the lining of the joints), juvenile arthritis (a form of joint disease in children), and ankylosing spondylitis (arthritis that mainly affects the spine). Prescription naproxen tablets, extended-release tablets, and suspension are also used to relieve shoulder pain caused by bursitis (inflammation of a fluid-filled sac in the shoulder joint), tendinitis (inflammation of the tissue that connects muscle to bone), gouty arthritis (attacks of joint pain caused by a build-up of certain substances in the joints), and pain from other causes, including menstrual pain (pain that happens before or during a menstrual period). Nonprescription naproxen is used to reduce fever and to relieve mild pain from headaches, muscle aches, arthritis, menstrual periods, the common cold, toothaches, and backaches. Naproxen is in a class of medications called NSAIDs. It works by stopping the body's production of a substance that causes pain, fever, and inflammation.

Active Substance: NAPROXEN

Naprosyn Available Drugs :

Naprosyn ndc# 0004-0028

by Genentech, Inc.

ORAL SUSPENSION with active strength of 125 mg/5mL

started marketing at 23/03/1987 .

Naprosyn ndc# 63629-3202

by Bryant Ranch Prepack

ORAL TABLET with active strength of 250 mg/1

started marketing at 01/09/2009 .

Naprosyn ndc# 0004-6313

by Genentech, Inc.

ORAL TABLET with active strength of 250 mg/1

started marketing at 11/03/1976 .

Naprosyn ndc# 0004-6314

by Genentech, Inc.

ORAL TABLET with active strength of 375 mg/1

started marketing at 11/03/1976 .

Naprosyn ndc# 0004-6316

by Genentech, Inc.

ORAL TABLET with active strength of 500 mg/1

started marketing at 11/03/1976 .

Naprosyn Search Trends:

News :

Social Buzz

comments powered by Disqus